11/5/2026

speaker
Cindy
Conference Operator

Good morning and welcome to the Inovus Third Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, Please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Kyle Rose, VP of Investor Relations. Please go ahead.

speaker
Kyle Rose
Vice President of Investor Relations

Good morning, everyone, and thank you for joining us today for our third quarter 2026 earnings conference call. I'm Kyle Rose, Vice President of Investor Relations. Joining me on the call this morning are Damien McDonald, Chief Executive Officer, and Ben Berry, our Chief Financial Officer. Our earnings release was issued earlier this morning and is available in the investor section of our website, anovis.com. We also posted a slide presentation to accompany today's call on our website. Both the audio and the slide presentation of this call will be archived on our website later today. During this call, we'll be making some forward-looking statements about our beliefs and estimates, regarding future events and results, including statements related to our pending acquisition of Essential Robotics. These forward-looking statements are subject to risks and uncertainties, including those set forth in the Safe Harbor language in today's earnings release and in our filings with the SEC. Actual results might differ materially from any forward-looking statements that we make today. The forward-looking statements speak only as of today, and we do not assume any obligation or intend to update them except as required by law. for further details regarding any non-GAAP financial measures referenced during this call. The accompanying reconciliation information can be found in our earnings press release and in the appendix of today's slide presentation. With that, let me turn it over to Damien.

speaker
Damien McDonald
Chief Executive Officer

Thanks, Kyle. Good morning, everyone, and thank you for joining us today. I'll start with an overview of our third quarter results across recon and P&R and give a short update on essential robotics. Ben will then walk through The financials and our outlook for the fourth quarter and the full year before we open the call for questions. In the third quarter, we delivered organic growth of 5% with 6% organic growth in recon and 3% in P&R. In US recon, we grew 5% organically with extremities up 5% and hips and knees up 3%. In extremities, we're now past the anniversary of the ARG launch and ARG continues to be a strong growth opportunity for the future. As planned, Arvis is expanding in shoulder and we build upon the launch that began in Q2. Shoulder remains a healthy market and it's where we have one of our leading share positions globally. In hips and knees, Nebula continues to drive growth with over 80% of new instrumentation sets going to competitive users in the quarter. While we've now annualized the launch of the Nebula in the US, we remain in the early stages of a multi-year product cycle. I'm proud to note that it is now our top-selling stem and we've got a long runway ahead of us. We're competing and winning in both hospital and ASC settings, and the ASC continues to be a good fit for our portfolio. Internationally, Recon grew 8% organically. As we've noted, the Past several quarters, market dynamics in Western Europe remain challenging, and the conflict in the Middle East continues to weigh on growth. Despite these challenges, Shoulder grew double digits and led the international business. We continue to win competitive accounts outside the US, and I'm excited to announce we completed the first Arvis Shoulder cases in Europe last month. On essential robotics, we announced our binding offer to acquire the company on September 1st. Since then, we have completed the Works Council consultation and we expect the deal to close by the end of the year. Integration planning is well underway. Our recon team is working with the essential team in Grenoble on the knee and shoulder programs and the timelines we laid out are unchanged. In fact, through our integration planning, we are making investments to secure the talent and technology required to accelerate our development upon deal close. We expect to bring the knee robot to market within two years and shoulder to follow soon thereafter. Since the announcement, I've spent a lot of time discussing robots with surgeons. What I hear most is how much opportunity there is to develop innovative enabling technology and implant systems which solve known problems and anticipate the evolution of surgical workflows and patient outcomes. This is an exciting inflection point for our recon business and we believe it will be a meaningful contributor to our sustained above-market growth. Now moving to P&R, which grew 3% organically, including 5% organic growth in the US. Global bracing grew 3%, driven by business mix and new products in spine, core, knees and lower extremity bracing segments. Recovery science was driven by double-digit growth in Regen as we accelerate the launch of Manifuse and capitalize on key competitive conversions. Now I'll turn it over to Ben, who will walk through the financial details.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation